DOI: 10.36347/sjams.2018.v06i08.045

Pages: 3165-3168

Paraoxonase 1 (PON1) is an esterase, synthesized and secreted by liver and found to be protective for both HDL and LDL against peroxidation, which suggests a possible involvement of PON1 in the anti-atherogenic properties of HDL. The present study was carried out to estimate the plasma parapxonase activity and erythrocyte malondialdehyde (marker of lipid peroxidation) in Stage I essential hypertensive subjects (HT) recruited as per JNC 7th norms and to determine their relation with each other in Stage I essential hypertensive patients. In the present study, plasma PON1 activity and malondialdehyde levels were measured in 50 Stage I essential hypertensive subjects (30-60 years) and statistically compared it with that of 50 healthy individual, served as control. Correlation analysis between aforesaid parameters was performed by using Pearson correlation test. Plasma PON1 activity was found to be significantly low in patient group as compared to control (P < 0.001) whereas erythrocyte malondialdehyde levels were increased significantly in patient group as compared to control (P < 0.001). Plasma PON1 activity was also inversely correlated with MDA in stage I essential hypertension patients. Thus, free radical mediated biomolecular destruction is the common pathway for vascular ageing and a variety of cardio vascular complications and body has a defense system of antioxidants which are involved in the prevention of free radical mediated cellular damage. From our study, it was concluded that increased lipid peroxidation and reduced plasma PON1 along with increase in blood pressure can be used as a marker for future cardiac complication in essential hypertension patients.